Overview

Sopherion Therapeutics, Inc. is a privately held biopharmaceutical company headquartered in Princeton, New Jersey and maintains preclinical R&D in New Haven, Connecticut, and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada.

Sopherion Therapeutics’ business strategy is: commercialize Myocet™ in North America; acquire or license one or several late stage development candidates in oncology or related areas; and to create a pre-clinical pipeline. In this process, Sopherion is leveraging its Minicell Peptide Display™ screening technologies to identify additional therapies.

The Company is focused on developing oncology and oncology-related therapies and is leveraging its Minicell Peptide Display™ screening technologies to identify additional therapies for cancer and related areas. Sopherion’s scientists have expertise and domain knowledge in the discovery, development and clinical management of oncology products with a strong emphasis in the angiogenesis, tumor invasion and metastasis fields.

Originally formed as an R&D company employing its proprietary technology platform for drug discovery, Sopherion has utilized its proprietary R&D platform to create a preclinical pipeline and to secure strategic partnerships with pharmaceutical companies with interest in peptide-based therapeutics; more recently, the Company has decided to spin out the R&D platform to a separate entity or otherwise largely divest itself of this asset. The Company has evolved to become a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd. for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada.